1:59 PM
Jun 22, 2018
 |  BioCentury  |  Finance

Bountiful, not bubbly

Why this week’s flurry of biotech IPOs on NASDAQ isn’t a sign of market froth

A compressed calendar, rather than investor overexuberance, accounts for one of the busiest weeks for IPO pricings in the sector’s history.

Seven NASDAQ IPOs were completed during the week ending June 22, raising a total of $718.9 million before potential overallotments.

Five of the deals priced on June 20, making for the single most active day for NASDAQ biotech IPOs since BioCentury began tracking financing data in 1994.

Five of the seven upsized their offerings, and one priced above the anticipated range.

The month’s total haul of $868.9 million is also the highest for June in the sector’s history, and the aggregate amount raised of $1.5 billion in 2Q18 is the second highest NASDAQ...

Read the full 547 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >